Treatment of cancer cells with the DNMT inhibitors 5-aza-dC, decitabine and zebularine show promise in reversal of repressive histone mark patterns and resensitization of ovarian cancer cells to chemotherapy [127,128], and several are currently in clinical trials [125,126]. This evidence concerns the gene DNMT1 and ovarian cancer.